A new biomarker tool for transgenic models of Parkinson’s disease
Check out our recent publication:
Singh S, Khayachi A, Milnerwood AJ, DeMarco ML. Quantitative profiling of synuclein species: Applications to transgenic mouse models of Parkinson's disease. Journal of Parkinson's Disease. 2020;10(2):614-621.
The LC-MS/MS approach had several advantages over ligand binding analytical methods, such as western blotting and enzyme-linked immunosorbent assays. These advantages included the ability to: quantify 1) total α-synuclein, 2) combined α- and β-synucleins, 3) species-specific contributions to total α-synuclein (e.g., in mice expressing both mouse and human α-synuclein), and 4) identify peptide-specific profile differences that may reflect post-translational modifications, all within a single analysis.
With improved and expanded analytical characteristics coupled with a streamlined sample preparation workflow, the quantitative synuclein profiling LC-MS/MS assay provides a versatile and efficient platform to characterize synuclein biology in pre-clinical models and the potential for application to human tissues and fluids.